EUVIMEDEUVIMED entdecken
Crossref

Nephrotoxicity of direct factor Xa inhibitors: a pharmacovigilance study using real-world data from the Federal Adverse Event Reporting System database

Xitong Zhang, Bing Lv, Bin Liu, Faping Li

Postgraduate Medical Journal · 2025

DOI: 10.1093/postmj/qgaf067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2025. Verfasst von Xitong Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Jilin Cancer Hospital, No. 1066, Jinhu Road, High-tech Zone, Changchun 130000, China. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Rivaroxaban, Pyrazoles, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Factor Xa inhibitors (FXaIs) may induce nephrotoxicity despite their FDA approval for thrombotic diseases, which has raised concerns due to its severe consequences. This study utilizes the FAERS database to assess the potential link between direct FXaIs and nephrotoxicity.

Methods

Data from the FAERS database, spanning from the third quarter of 2011 to the fourth quarter of 2023, were used to perform a disproportionality analysis on Apixaban, Edoxaban, and Rivaroxaban. Disproportionality analysis and statistical processing were conducted using R software.

Results

Descriptive analysis revealed that males and individuals aged 65–85 are more susceptible to nephrotoxic adverse events. The disproportionality analysis indicated that all three drugs are associated with acute renal failure and renovascular disorders, with Edoxaban showing the strongest correlation.

Conclusions

This study quantitatively analysed the relative risk of nephrotoxic adverse reactions associated with direct FXaIs, emphasizing the importance of renal function monitoring for these medications. The results indicate that Edoxaban has a significant association with nephrotoxicity, necessitating closer attention to its use and recommending additional renal function tests and drug concentration testing for high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsRivaroxabanPyrazolesPyridinesThiazolesAcute Kidney InjuryHumansMaleAgedFemaleAged, 80 and overPharmacovigilanceAdverse Drug Reaction Reporting SystemsDatabases, FactualPyridonesMiddle AgedUnited StatesAdult

Stichwörter der Autor:innen

FAERSdata miningfactor Xa inhibitorsnephrotoxicitypharmacovigilance

Substanzen

Factor Xa InhibitorsedoxabanapixabanRivaroxabanPyrazolesPyridinesThiazolesPyridones

Autor:innen und Institutionen

  • Department of Anesthesiology, Jilin Cancer Hospital, No. 1066, Jinhu Road, High-tech Zone, Changchun 130000, China.
  • Department of Emergency, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, China.
  • Department of Urology II, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, China.

Zitieren

APA

Zhang, X., Lv, B., Liu, B., & Li, F. (2025). Nephrotoxicity of direct factor Xa inhibitors: a pharmacovigilance study using real-world data from the Federal Adverse Event Reporting System database. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf067

Vancouver

Zhang X, Lv B, Liu B, Li F. Nephrotoxicity of direct factor Xa inhibitors: a pharmacovigilance study using real-world data from the Federal Adverse Event Reporting System database. Postgraduate Medical Journal. 2025. doi:10.1093/postmj/qgaf067

BibTeX
@article{Zhang2025,
  author = {Zhang, Xitong and Lv, Bing and Liu, Bin and Li, Faping},
  title = {Nephrotoxicity of direct factor Xa inhibitors: a pharmacovigilance study using real-world data from the Federal Adverse Event Reporting System database},
  journal = {Postgraduate Medical Journal},
  year = {2025},
  doi = {10.1093/postmj/qgaf067}
}
Kostenlos starten →